Geode Capital Management LLC Raises Stock Holdings in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

Geode Capital Management LLC increased its holdings in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 23.7% in the third quarter, according to its most recent filing with the SEC. The fund owned 3,562,758 shares of the company’s stock after acquiring an additional 682,273 shares during the period. Geode Capital Management LLC’s holdings in Taysha Gene Therapies were worth $7,163,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the business. Creative Planning purchased a new stake in Taysha Gene Therapies in the third quarter worth $28,000. Principal Financial Group Inc. bought a new position in shares of Taysha Gene Therapies in the second quarter worth about $48,000. China Universal Asset Management Co. Ltd. increased its stake in Taysha Gene Therapies by 79.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 39,417 shares of the company’s stock worth $79,000 after buying an additional 17,446 shares during the period. Intech Investment Management LLC bought a new stake in Taysha Gene Therapies during the 3rd quarter valued at about $85,000. Finally, Scientech Research LLC purchased a new stake in Taysha Gene Therapies in the 2nd quarter valued at about $97,000. Hedge funds and other institutional investors own 77.70% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on TSHA shares. Chardan Capital reaffirmed a “buy” rating and set a $7.00 target price on shares of Taysha Gene Therapies in a research report on Thursday, November 14th. Cantor Fitzgerald restated an “overweight” rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a report on Tuesday, November 12th. JMP Securities reiterated a “market outperform” rating and issued a $5.00 target price on shares of Taysha Gene Therapies in a report on Tuesday, November 12th. Needham & Company LLC reissued a “buy” rating and set a $6.00 price target on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Finally, Canaccord Genuity Group lifted their price objective on Taysha Gene Therapies from $6.00 to $8.00 and gave the company a “buy” rating in a report on Friday, November 15th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $6.63.

Taysha Gene Therapies Trading Up 6.9 %

Shares of NASDAQ:TSHA opened at $1.85 on Friday. The company has a market capitalization of $379.14 million, a PE ratio of 2.94 and a beta of 0.79. The company has a current ratio of 5.51, a quick ratio of 5.51 and a debt-to-equity ratio of 0.48. Taysha Gene Therapies, Inc. has a 12-month low of $1.19 and a 12-month high of $4.32. The business’s fifty day simple moving average is $2.10 and its 200-day simple moving average is $2.18.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.